Figure 3.

GPR52 is involved in de novo synthesis of fatty acid and cholesterol in mice tissues and a human hepatoma cell line

(A and B) Thin-layer chromatography (TLC) images of de novo synthesis of fatty acid and cholesterol labeled by ¹⁴C-acetate in epiWAT (A) and liver (B). The radioactivity (PSL: photostimulated luminescence) of fatty acid and cholesterol in Gpr52^-/- and WT mice (n = 5) (right). Data are means ± SEM. ∗p <0.05, between the animal groups by unpaired Student's t test.

(C) The effect of GPR52 agonist c11 on cAMP production in HepG2 cells treated with GPR52 siRNA or control siRNA (n = 3). The cAMP levels were normalized by protein concentration.

(D) The effect of GPR52 agonist c11 on de novo synthesis of fatty acid and cholesterol in HepG2 cells treated with GPR52 siRNA or control siRNA indicated as TLC image (n = 3).

(E and F) The radioactivity (PSL) of fatty acid (E) and cholesterol (F) of TLC image.

(G) The effect of GPR52 agonist c11 on gene expressions of fatty acid and cholesterol biosynthesis in HepG2 cells treated with GPR52 siRNA or control siRNA (n = 3).

Data are means ± SEM. ^#p < 0.05, ^##p < 0.01, versus c11-untreated, control siRNA-treated cells by unpaired Student's t test. ∗p < 0.05, ∗∗p < 0.01, versus control siRNA-treated, c11 treatment counterparts by unpaired Student's t test. See also Figure S2.